Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus HYDRODIURIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus HYDRODIURIL.
DYAZIDE vs HYDRODIURIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
None Documented
None Documented
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic